Plain-English translation of NCT06032923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing nicotinamide riboside, a supplement related to vitamin B3, to see if it can help calm down the overactive immune system in women with lupus. Lupus is an autoimmune disease where the body's immune system attacks its own tissues, causing inflammation and fatigue. Researchers believe this medication may help by improving how immune cells use energy, which could reduce harmful inflammation.
Women with lupus have immune cells that don't work properly and are overactive, leading to inflammation throughout the body and heart problems. There is a need for new treatments that address the root cause of this immune problem rather than just managing symptoms.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will either take daily capsules of the medication or a placebo (inactive pill) for 6 weeks—you won't know which one you're receiving. You'll have blood tests at the start and end of the study to measure changes in your immune cells and inflammation. A healthy control group will also participate but won't receive any medication; they'll only have blood drawn once for comparison.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States